At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Antiretroviral treatment pausedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·observational·Posted Dec 22, 2016·Updated Dec 13, 2024
In Brief
An observational study evaluating Antiretroviral treatment pause for HIV-1 Infection. Completed, enrolled 61 participants across 18 sites in 3 countries.
Detailed Summary
The purpose of this study is to collect information about what happens when people pause, or temporarily stop taking, ART, and to collect blood samples from these people at frequent intervals. We will also study the safety of pausing ART under close observation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV-1 Infection
CountriesPuerto Rico, Thailand, United States
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartFeb 2017
Primary CompletionJan 2021
TodayJul 2026
First PostedDec 22, 2016
Enrollment StartFeb 23, 2017
Primary CompletionJan 29, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.5 years ago
Interventions
Antiretroviral treatment pausedrug
Antiretroviral treatment pause